Elan Pharmaceuticals

Company snapshot

Elan is a neuroscience-focused biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984. Elan's work includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease and autoimmune diseases, including multi

• 18 active pipeline program(s) linked via ClinicalTrials.gov.
• 18 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Elan Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Elan Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   HZNP-DAX-202 — Phase 2

2. Jun 8, 2026 Clinical update

   VIB0551.P3.S2 — Phase 3

3. Jun 8, 2026 Clinical update

   VIB0551.P3.S1 — Phase 3

4. Jun 8, 2026 Clinical update

   HZNP-HZN-825-303 — Phase 2

5. Jun 8, 2026 Clinical update

   HZNP-DAZ-301 — Phase 3

View all clinical trial activity →

• What is Elan Pharmaceuticals?

  Elan Pharma International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State, Breast Neoplasms, Lentigo Maligna. NovaPharmaNews links 18 clinic

• Is Elan Pharmaceuticals publicly traded?

  Elan Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Elan Pharmaceuticals develop or market?

  We link 26 drug profile(s) where Elan Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/elan-pharma-international#company-drugs.

• What are the latest developments for Elan Pharmaceuticals?

  In the last 12 months our linked public records show 18 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Elan Pharmaceuticals focus on?

  Elan Pharmaceuticals focuses on Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State based on our analysis of their pipeline programs and drug development activities.